Shionogi & Co., Ltd. has continued its partnership with the ALS/MND Natural History Consortium to collect and analyse real-world data on amyotrophic lateral sclerosis, including information involving Radicava ORS (edaravone), its approved oral ALS treatment. The collaboration follows Shionogi’s acquisition of global rights to Radicava ORS and intravenous Radicava and will use the NeuroBANK observational platform to study disease progression and treatment use across routine multidisciplinary care.
Why Shionogi’s ALS data strategy matters more after acquiring global Radicava rights
The partnership has greater strategic significance because Shionogi is no longer an outside research collaborator examining the ALS treatment landscape. It is now the global owner of an established edaravone franchise acquired through a transaction involving an upfront payment of $2.5 billion, potential future royalties and a commercial business expected to contribute approximately $700 million in annual global sales.
That investment gives Shionogi a strong incentive to build a more detailed understanding of how edaravone is used beyond the relatively controlled environment of registration trials. The Japanese pharmaceutical group has acquired a medicine, an experienced commercial organisation and relationships across specialist ALS centres, but it has also inherited unresolved evidence questions surrounding treatment selection, persistence, clinical outcomes and the generalisability of the original pivotal study.
NeuroBANK can potentially help close some of those gaps by allowing Shionogi and academic researchers to examine longitudinal clinical information collected during normal care. That could strengthen medical affairs planning, support future study hypotheses and reveal differences between trial participants and the broader population receiving treatment. However, access to more data does not automatically produce stronger evidence. The value of the collaboration will depend on whether the analyses are prespecified, clinically relevant and sufficiently rigorous to separate treatment effects from differences between patients.
How NeuroBANK could clarify ALS progression and treatment use outside clinical trials
The ALS/MND Natural History Consortium has enrolled more than 4,500 people living with ALS across 18 multidisciplinary clinics in the United States, Europe and Israel. NeuroBANK enables participating centres to capture standardised longitudinal information during routine visits, creating a dataset that reflects a wider range of disease stages, progression rates, treatment patterns and clinical backgrounds than would usually be represented in a tightly selected clinical trial.
This is particularly important in ALS because the disease is highly heterogeneous. Some people initially develop limb weakness, while others present with speech or swallowing difficulties. Rates of functional decline can vary substantially, and genetic status, respiratory function, age, time from symptom onset and access to specialist care can all influence observed outcomes.
A large natural history dataset can help researchers identify clinically meaningful subgroups and understand which baseline characteristics are associated with faster or slower progression. It may also reveal how often patients start edaravone, whether they remain on treatment, how oral and intravenous use differs, and how therapy is combined with other available ALS medicines.
The limitations are equally important. Patients treated at multidisciplinary specialist centres may not represent people receiving care in smaller hospitals or underserved regions. Follow-up intervals can vary, clinical assessments may be missing when disease worsens, and patients receiving edaravone may differ systematically from untreated patients. Those receiving treatment may be younger, diagnosed earlier, more engaged with specialist care or healthier at baseline, creating confounding that cannot be fully eliminated through statistical adjustment.
Why real-world edaravone evidence is valuable but cannot settle every efficacy question
Edaravone’s regulatory history explains why broader observational evidence is attractive. The original development programme included an initial Phase 3 study that did not demonstrate a statistically significant overall benefit. A subsequent analysis identified a narrower group with earlier-stage disease, relatively preserved respiratory function and stronger baseline functional status.
The confirmatory Study 19 then prospectively enrolled 137 participants matching that more restricted profile. After 24 weeks, patients receiving edaravone experienced less decline on the 48-point ALS Functional Rating Scale-Revised than those receiving placebo, with an adjusted treatment difference of approximately 2.5 points.
That result supported approval, but it also left questions about how well the findings extend to patients with more advanced disease, longer disease duration, poorer respiratory function or clinical characteristics outside the pivotal eligibility criteria. A multinational real-world dataset could provide valuable information about those populations and help determine whether outcome patterns are consistent across a broader range of patients.
Observational analyses cannot simply recreate the certainty of a randomised trial. Clinicians choose treatments for specific reasons, and those reasons may also influence outcomes. A patient who begins edaravone soon after diagnosis may differ from someone who does not receive it in ways that are difficult to measure, including socioeconomic resources, caregiver support, insurance access, clinic proximity and willingness to undertake long-term therapy.
Any comparative effectiveness analysis will therefore require careful control of baseline disease severity, progression before treatment, respiratory status, concomitant therapies and treatment timing. Even sophisticated methods such as propensity-score matching or target-trial emulation cannot correct for factors that were never captured. Real-world evidence can strengthen understanding of clinical practice, but it should not be treated as an automatic substitute for randomisation.
What the collaboration could change for future ALS clinical trial design
NeuroBANK’s most durable contribution may be in designing better trials rather than attempting to replace control groups entirely. Reliable natural history data can help developers estimate expected progression rates, identify patient characteristics linked to outcome variability and determine how many participants are required to detect a clinically meaningful treatment effect.
The dataset could also improve enrichment strategies. Developers may be able to select participants whose disease is likely to progress at a measurable rate during the study period, reducing the risk that highly variable natural progression obscures a genuine drug effect. Better progression models may also support stratified randomisation, more balanced treatment groups and more accurate interpretation of ALS Functional Rating Scale-Revised results.
Regulators have historically been cautious about ALS trials relying entirely on historical controls because progression and survival rates differ significantly across individuals and study populations. Natural history information may become more useful as datasets grow larger, measurements become more consistent and statistical methods improve, but a registry cohort is not interchangeable with a concurrently randomised placebo group.
The most credible near-term use may therefore involve supporting trial planning, contextualising findings, reducing unnecessary placebo exposure or supplementing evidence from controlled studies. Shared infrastructure may also help identify suitable sites and reduce recruitment delays, which remain major barriers in rare neurodegenerative disease development.
How the partnership strengthens Shionogi’s commercial platform without proving superiority
The collaboration fits a broader transformation of Shionogi’s rare disease business. Through the Radicava acquisition, the pharmaceutical group gained global product rights, experienced personnel and an established United States commercial platform that could eventually support additional rare disease launches.
Real-world data can help that organisation understand treatment pathways and identify where patients discontinue therapy, switch formulations or encounter access barriers. Such information can guide educational programmes, evidence-generation priorities and discussions with healthcare systems or payers. It could also help Shionogi evaluate whether the oral formulation is reducing some of the logistical burden associated with repeated intravenous administration.
However, the partnership should not be interpreted as evidence that Radicava ORS is superior to other ALS therapies or that broader use will necessarily produce better outcomes. There are no robust head-to-head trials establishing superiority between edaravone, riluzole and genetically targeted treatments. The available medicines also differ in mechanism, route, eligible population and regulatory evidence.
Commercial ownership creates an additional need for transparent governance. Analyses involving a sponsor-owned medicine will be more persuasive when research questions are defined before data examination, statistical methods are disclosed and results are made available regardless of whether they favour the product. Academic independence and publication transparency will determine whether clinicians regard the evidence as scientific research or primarily as lifecycle management.
Why ALS treatment comparisons are becoming more complex as therapies diverge
The ALS treatment landscape increasingly includes both broadly indicated medicines and therapies developed for molecularly defined subgroups. Riluzole and edaravone can be prescribed across a broad ALS population, while tofersen is designed for adults with ALS associated with a mutation in the superoxide dismutase 1 gene.
Tofersen also illustrates how ALS regulation is evolving. Its accelerated approval was based on a reduction in plasma neurofilament light, a biomarker associated with neuronal injury, rather than a statistically significant result on the primary functional endpoint of its pivotal study. That approach reflects regulatory flexibility in a severe rare disease, but it also reinforces the importance of confirmatory evidence and long-term follow-up.
A real-world platform could eventually help researchers examine treatment combinations, genetic subgroups and the relationship between biomarkers and functional decline. It could also reveal whether the same clinical measures behave consistently across sporadic ALS and genetically defined disease.
Those comparisons must remain cautious. A treatment aimed at a specific genetic driver cannot be directly compared with a broadly indicated therapy without accounting for fundamental differences in patient biology. Combination use also makes attribution difficult because a patient may receive riluzole, edaravone and supportive interventions simultaneously. Larger datasets improve statistical power, but they do not remove the need for biologically informed study design.
What clinicians and regulators will watch as the ALS partnership generates evidence
The first test will be whether Shionogi and the consortium define focused clinical questions rather than conducting broad exploratory searches across thousands of variables. Studies examining treatment initiation, discontinuation, functional decline or respiratory outcomes will need clearly defined index dates, comparable patient groups and transparent handling of missing data.
Clinicians will also watch whether the analyses capture the full spectrum of ALS rather than concentrating on patients who most closely resemble the pivotal edaravone population. Evidence from people with later-stage disease, bulbar-onset symptoms, lower respiratory function or longer disease duration could address important knowledge gaps, but those groups may also have more incomplete follow-up and greater clinical complexity.
Regulatory relevance will depend on data quality, consistency between clinics and whether outcomes are measured frequently enough to support reliable longitudinal analysis. Demonstrating that information is collected during routine visits with limited patient burden is an operational advantage, but convenience must not come at the expense of endpoint precision.
The partnership therefore gives Shionogi access to a valuable scientific and commercial resource at a critical point in the Radicava franchise. It can improve understanding of ALS care, support better trial design and generate evidence across populations not fully represented in registration studies. Its impact will ultimately be determined not by the size of the dataset, but by whether the resulting analyses are methodologically credible, clinically meaningful and transparent about the conclusions that observational data cannot support.
